Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation
Lindy Biosciences, a pioneering biotechnology company specializing in innovative drug formulation and delivery technologies, today announced a multi-target exclusive global licensing agreement and strategic collaboration with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS), an innovative medicines company.
The collaboration will focus on transitioning select innovative medicines from the Novartis portfolio to convenient, self-administered subcutaneous injections using Lindy Biosciences’ proprietary microglassification suspension technology. By delivering high concentrations of biologics, this technology significantly increases the maximum dose that can be administered in a single subcutaneous injection. This has the potential to reduce healthcare costs while also improving patient comfort, convenience, and treatment compliance.
Currently, over half of all antibody therapeutics are administered intravenously in a clinical setting, primarily due to the high doses required that cannot be formulated in volumes suitable for subcutaneous injection. Lindy Biosciences’ proprietary microglassification platform technology is poised to transform this paradigm by enabling self-administration at home via pre-filled syringes or autoinjectors.
Strategic Impact and Future Outlook
Dr. Deborah Bitterfield, founder and CEO of Lindy Biosciences, expressed enthusiasm about the collaboration: "We're excited to deepen our collaboration with Novartis. This collaboration is a testament to our shared dedication to enhancing patient care and marks a significant milestone as we take Lindy’s formulation technology into the clinic for the first time. Together, we aim to transform drug delivery and improve treatment access for patients worldwide."
The agreement's financial terms include an upfront payment of US$20 million to Lindy Biosciences. Lindy Biosciences is also eligible to receive up to US$934 million in additional payments across multiple targets upon achieving certain regulatory, development and commercial milestones as well as tiered single-digit royalties on net sales.
This collaboration marks a significant step forward in addressing the growing need for patient-friendly treatment options that can be self-administered at home. By combining innovative technology from Lindy Biosciences and the global reach and expertise of Novartis, the collaboration promises to usher in a new era of drug delivery, reshaping patient care on a global scale.
About Lindy Biosciences
Lindy Biosciences is dedicated to transforming the delivery of biologic drugs and improving patients' lives through innovative biotherapeutic formulations. Our cutting-edge solutions are designed to enhance drug formulation and delivery, specializing in the subcutaneous administration of concentrated (>400 mg/mL) biologic suspensions.
Founded in 2016 and headquartered in Morrisville, NC, Lindy Biosciences leverages core microglassification technology originated at Duke University and further developed by the company. We are committed to partnering with leading pharmaceutical companies to advance treatment accessibility for patients worldwide.
For more information, visit us at www.lindybio.com or follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827920051/en/
Contacts
media@lindybio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dr. Wolff Group Working with Kinaxis and mSE Solutions to Bring Supply Chain Clarity to Personal Care Product Portfolio10.9.2024 14:52:00 EEST | Press release
Kinaxis® Inc. (TSX: KXS), a global leader in end-to-end supply chain orchestration, today announced that Dr. Wolff Group, a family-owned German manufacturer of cosmetic and pharmaceutical products, is working with Kinaxis, along with mSE Solutions, an expert supply chain optimization consultancy, to help drive faster and more accurate decision-making in supply chain planning and thus ensure a better balance between market and supply chain dynamics. A growing company that exports its popular brands including Alpecin, Alcina, and Plantur among others, to more than 60 countries worldwide, Dr. Wolff faced challenges in managing its complex and diverse product portfolio that includes everything from hair care and styling products, to decorative cosmetics, dental care, and vaginal and dermatologic pharmaceuticals. In order to be able to react even more flexibly, quickly and efficiently to customer requirements, the company turned to mSE Solutions and Kinaxis to strengthen its supply chain pr
Total Economic Impact Study Reveals a Return on Investment of 184% for Veracode Application Risk Management Platform Customers10.9.2024 14:50:00 EEST | Press release
Veracode, a global leader in application risk management, today released a commissioned study conducted by Forrester Consulting on The Total Economic Impact™ (TEI) of Veracode’s Application Risk Management Platform. The study revealed that Veracode delivered a 184 percent return on investment (ROI) to customers over a three-year period, as well as a material Net Present Value and a payback period of less than six months. Specifically, there were four key drivers of the economic impact: A 75 percent reduction in risk of software-based attacks 80 percent developer productivity recapture that can be reallocated to product innovation 85 percent efficiency gained in application security from increased automation Most noteworthy, a 20 percent growth in revenues from software security that drove new products, new market entries, speed to market, and security as a differentiator With software supply chain attacks on the rise, security and DevSecOps leaders need ways to source solutions that de
Delta-Fly Pharma Inc.: Phase I/II Combo-study of DFP-10917 with Venetoclax in Patients with AML Initiates Enrollment of Patients10.9.2024 14:00:00 EEST | Press release
Following to the previous information on April 8th. 2024, we are excited to share our latest development status. A Phase I/II clinical trial of DFP-10917 in combination with Venetoclax (VEN) in patients with acute myeloid leukemia (AML) who had one prior treatment with VEN involved regimen was approved by the US Food and Drug Administration (FDA) on April 8 this year (Delta-Fly Pharma Inc.: Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 combined with Venetoclax | Business Wire). Subsequently, we are pleased to announce that the first patient was enrolled at the University of Virginia Hospital based on the approval of the Investigational Review Board (IRB). The University of Virginia Hospital is the clinical site that enrolled the most patients to the Phase III study of DFP-10917 monotherapy in patients with failed/relapsed AML. Some pharmaceutical companies have already expressed interest in the Phase III study of DFP-10917 monotherapy. Additionally, many companie
SLB achieves breakthrough results in sustainable lithium production10.9.2024 13:56:00 EEST | Press release
SLB today announced it has proven its solution for sustainable lithium production at scale at its demonstration plant in Clayton Valley, Nevada, to accelerate responsibly-sourced lithium products to market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240909767336/en/ SLB's demonstration plant in Clayton Valley proves its unique integrated approach to produce scalable quantities of lithium in the fastest, most economical and sustainable way for today’s market. (Photo: Business Wire) The proprietary integrated solution combines SLB’s subsurface expertise with surface engineering of advanced technologies that include direct lithium extraction (DLE). It produces lithium 500 times faster than conventional methods while using only 10 percent of the land. Operating at approximately one tenth the size of a commercial-scale facility, the plant reached a verified recovery rate1 of 96% lithium from brine. SLB’s integrated solution i
Eaton to Showcase Technologies for Hydrogen-Powered Commercial Vehicles at IAA Transportation 202410.9.2024 13:30:00 EEST | Press release
Intelligent power management company Eaton announced it will showcase a broad range of innovative solutions for hydrogen-powered commercial vehicles September 17–22 at IAA Transportation 2024 in Hanover, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910157651/en/ Eaton’s hydrogen recirculation blower cycles surplus hydrogen to the stack's inlet, which extends system longevity through anode purging. (Photo: Business Wire) “Eaton believes that hydrogen can play a significant role in decarbonizing commercial vehicles,” said Scott Adams, senior vice president, Global Products, Eaton’s Mobility Group. “Whether a vehicle is powered by hydrogen fuel cells or a hydrogen internal combustion engine, Eaton’s broad range of innovative solutions makes us a valuable supplier partner.” Eaton’s TVS technology improves fuel cell performance Recirculating excess hydrogen through the fuel cell stack is critical for achieving high
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom